NGNE - NASDAQ

Neurogene Inc.

NGNE·NASDAQ

$26.22

+0.31%

HealthcareBiotechnology

Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$414.33M

EPS-4.2400

P/E Ratio-6.18

Earnings Date08/07/2026

ngne

Free Cash Flow

Last Annual Value

-78.36M

3-Year CAGR

-12%

5-Year CAGR

-24%

10-Year CAGR

-14%

Adjust for Inflation

Neurogene Inc. Competitors Analysis of Free Cash Flow

NGNE · NASDAQ

Company	Free Cash Flow	CAGR 3Y	CAGR 5Y	CAGR 10Y
Neurogene Inc. NASDAQ:NGNE	-78.36M	N/A	N/A	N/A
Ocugen, Inc. NASDAQ:OCGN	-57.15M	N/A	N/A	N/A
Alumis Inc. Common Stock NASDAQ:ALMS	-370.18M	N/A	N/A	N/A
Rocket Pharmaceuticals, Inc. NASDAQ:RCKT	-190.45M	N/A	N/A	N/A
4D Molecular Therapeutics, Inc. NASDAQ:FDMT	-109.08M	N/A	N/A	N/A
Inhibrx Biosciences, Inc. NASDAQ:INBX	-129.82M	N/A	N/A	N/A
MBX Biosciences, Inc. Common Stock NASDAQ:MBX	-81.88M	N/A	N/A	N/A
Benitec Biopharma Inc. NASDAQ:BNTC	-23.61M	N/A	N/A	N/A
Lineage Cell Therapeutics, Inc. AMEX:LCTX	-19.44M	N/A	N/A	N/A
PureTech Health plc NASDAQ:PRTC	-85.34M	N/A	N/A	N/A
Fulcrum Therapeutics, Inc. NASDAQ:FULC	-60.38M	N/A	N/A	N/A

Neurogene Inc. Fair Value Envelope

NGNE · NASDAQ

Our analysis suggests that NGNE has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $26.22, this represents a potential HIDDEN relative to our calculated worth for Neurogene Inc..

HIDDEN

Intrinsic Value

Current Price: $26.22

Related Guides

Blog Categories

Continue your NGNE research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.